Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Journal: British journal of cancer
Published: November 24, 2022
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Journal: British journal of cancer
Published: May 04, 2022
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 18, 2020
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Journal: The Lancet. Oncology
Published: March 18, 2019
Validated competing event model for the stage I-II endometrial cancer population.
Journal: International journal of radiation oncology, biology, physics
Published: January 06, 2014
Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: a population-based study.
Journal: Journal of the National Cancer Institute
Published: October 15, 2013
Showing 1-7 of 7
Last Updated: 09/26/2026